development pipeline graphic


ORP-101 is a new chemical entity designed with intent to create a large stable molecule and to confer partial μ agonist and full κ-antagonist receptor pharmacology. 

Key highlights:

  • FDA Fast Track designation for IBS-D
  • No opioid-like CNS effects
  • Safe and well tolerated in Phase 1 studies
  • Successful Phase 2 study
  • Exploring additional indications for post-IBD IBS and pancreatic pain

ORP-105 is a non-addictive, centrally-acting, non-opiate analgesic that targets the same receptors as acetaminophen but does not form metabolites that cause liver injury.


ORP-110 is a discovery-stage, metabolically-stable P2Y receptor ligand for treating diseases associated with secretory dysfunction.